We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

44 hedge funds and large institutions have $7.71M invested in Quince Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

5% more funds holding

Funds holding: 42 → 44 (+2)

0% less ownership

Funds ownership: 0.09% → 0.08% (-0%)

2% less capital invested

Capital invested by funds: $7.84M → $7.71M (-$128K)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
44
Holders Change
+2
Holders Change %
+4.76%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
11
Closed
5
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
+$20K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$199K
2
Renaissance Technologies
Renaissance Technologies
New York
+$76.5K
3
ACM
ADAR1 Capital Management
Texas
+$33.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$32.8K
5
IC
IEQ Capital
California
+$28.1K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$338K
2
Jane Street
Jane Street
New York
-$126K
3
ECG
EPIQ Capital Group
California
-$30.3K
4
XT
XTX Topco
Cayman Islands
-$22.5K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$15.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Westmount Partners
California
$10.6K -$248 -1 -2%
Morgan Stanley
27
Morgan Stanley
New York
$8.9K -$12.2K -49 -54%
TRCT
28
Tower Research Capital (TRC)
New York
$7.71K +$497 +2 +6%
Citigroup
29
Citigroup
New York
$5.47K – – –
Simplex Trading
30
Simplex Trading
Illinois
$4K +$5.22K +21 +700%
Group One Trading
31
Group One Trading
Illinois
$1.7K +$1.99K +8 New
Fidelity Investments
32
Fidelity Investments
Massachusetts
$1.59K +$1.99K +8 New
UBS Group
33
UBS Group
Switzerland
$536 – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$497 – – –
CA
35
CoreCap Advisors
Michigan
$457 +$497 +2 New
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$417 – – –
JFG
37
JDM Financial Group
Texas
$360 – – –
PA
38
Parallel Advisors
California
$330 -$2.48K -10 -83%
FP
39
Financial Perspectives
Minnesota
$329 – – –
Osaic Holdings
40
Osaic Holdings
Arizona
$293 – – –
Wells Fargo
41
Wells Fargo
California
$284 -$1.24K -5 -83%
FA
42
Financial Avengers
California
$109 – – –
Barclays
43
Barclays
United Kingdom
$106 – – –
WIM
44
Westside Investment Management
California
$80 – – –
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$25 – – –
Jane Street
46
Jane Street
New York
– -$126K -599 Closed
XT
47
XTX Topco
Cayman Islands
– -$22.5K -107 Closed
Two Sigma Investments
48
Two Sigma Investments
New York
– -$13.8K -66 Closed
TSS
49
Two Sigma Securities
New York
– -$12.6K -60 Closed
ASN
50
Advisory Services Network
Georgia
– -$1.1K -5 Closed
1
2

QNCX Hedge Fund Activity: Q1 2024 in Review

44 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2024, worth a combined $7.71M — down 1.6% from $7.84M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new QNCX positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $199K. The largest seller was Tang Capital Management, cutting an estimated $338K.

  • 44 institutional investors held Quince Therapeutics (QNCX) as of Q1 2024, up from 42 in Q4 2023.
  • Funds reported $7.71M of Quince Therapeutics stock for Q1 2024, down 1.6% quarter-over-quarter.
  • 7 funds opened new Quince Therapeutics positions in Q1 2024 and 5 closed out, a net change of +2 holders.
  • The largest Quince Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $199K added.
  • The largest Quince Therapeutics seller in Q1 2024 was Tang Capital Management, an estimated $338K sold.

Based on aggregated 13F filings for Q1 2024.